Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck
Nineteen patients, nine men and 10 women, with advanced adenoid cystic carcinoma (ACC), were treated with cisplatin either alone or in combination with doxorubicin and bleomycin. Median age was 51 years (range: 32-73 years). Two groups of patients were distinguished: Group 1 (N = 10) received single...
Saved in:
Published in | Head & neck Vol. 14; no. 4; p. 273 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.07.1992
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Nineteen patients, nine men and 10 women, with advanced adenoid cystic carcinoma (ACC), were treated with cisplatin either alone or in combination with doxorubicin and bleomycin. Median age was 51 years (range: 32-73 years). Two groups of patients were distinguished: Group 1 (N = 10) received single-agent cisplatin (50-120 mg/m2 IV every 4 weeks) for locoregional recurrence (N = 4), pulmonary metastases (N = 5), or as neoadjuvant therapy (N = 1). Five patients failed previous chemotherapy. No objective responses were observed, five patients showed stabilization of their disease for a median duration of 20 months (range: 3-50 months). Group 2 (N = 9) received a combination of cisplatin (20 mg/m2 IV on days 1-5), doxorubicin (50 mg/m2 IV on day 1), and bleomycin (30 mg IV on days 1-5), every 3 weeks. A complete remission (CR) was seen in one patient, lasting for 2 years, a partial remission (PR) in two patients (duration: 6 months and 6 years) (33%), and a stable disease (SD) in five patients (median duration: 15 months; range 3-24 months). One patient showed progression from the start. The observed toxicity was acceptable: dose reduction was required in five patients for myelosuppression or impairment of renal function; vomiting grade III (WHO) was seen in 10 patients. The median progression-free survival was 36 months (range: 7-77 months). Median overall survival was 81 months (range: 14-216 months). The role of cisplatin in this disease remains questionable. |
---|---|
AbstractList | Nineteen patients, nine men and 10 women, with advanced adenoid cystic carcinoma (ACC), were treated with cisplatin either alone or in combination with doxorubicin and bleomycin. Median age was 51 years (range: 32-73 years). Two groups of patients were distinguished: Group 1 (N = 10) received single-agent cisplatin (50-120 mg/m2 IV every 4 weeks) for locoregional recurrence (N = 4), pulmonary metastases (N = 5), or as neoadjuvant therapy (N = 1). Five patients failed previous chemotherapy. No objective responses were observed, five patients showed stabilization of their disease for a median duration of 20 months (range: 3-50 months). Group 2 (N = 9) received a combination of cisplatin (20 mg/m2 IV on days 1-5), doxorubicin (50 mg/m2 IV on day 1), and bleomycin (30 mg IV on days 1-5), every 3 weeks. A complete remission (CR) was seen in one patient, lasting for 2 years, a partial remission (PR) in two patients (duration: 6 months and 6 years) (33%), and a stable disease (SD) in five patients (median duration: 15 months; range 3-24 months). One patient showed progression from the start. The observed toxicity was acceptable: dose reduction was required in five patients for myelosuppression or impairment of renal function; vomiting grade III (WHO) was seen in 10 patients. The median progression-free survival was 36 months (range: 7-77 months). Median overall survival was 81 months (range: 14-216 months). The role of cisplatin in this disease remains questionable. |
Author | De Mulder, P H de Haan, L D Vermorken, J B Schornagel, J H Verweij, J Vermey, A |
Author_xml | – sequence: 1 givenname: L D surname: de Haan fullname: de Haan, L D organization: Department of Medical Oncology, St. Radboundhospital, Nijmegen, The Netherlands – sequence: 2 givenname: P H surname: De Mulder fullname: De Mulder, P H – sequence: 3 givenname: J B surname: Vermorken fullname: Vermorken, J B – sequence: 4 givenname: J H surname: Schornagel fullname: Schornagel, J H – sequence: 5 givenname: A surname: Vermey fullname: Vermey, A – sequence: 6 givenname: J surname: Verweij fullname: Verweij, J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/1381339$$D View this record in MEDLINE/PubMed |
BookMark | eNotzzFPwzAQBWAPRaUtrGxI_gMpZ58bJyOqgCJVYgHW6mxfFEPjRElAyr8nEp3e8D496a3FIrWJhbhTsFUA-qHmsNVFAcqAAVyIlQKDGYI112I9DF8AgLnRS7FUWCjEciU-93HozjTGlDkaOEhfc9OONffUTTImSeGXkp8LCpzaOINpGKOXnnofU9uQbCs5e1kzzSgFmdh_34iris4D315yIz6en973h-z49vK6fzxm3ljEzGldOibPXhUuQG7ROesgOEKVY1C6zCloVXpA3gWkQpmdrYy1howLJemNuP_f7X5cw-HU9bGhfjpd_uk_ZixSdA |
CitedBy_id | crossref_primary_10_1097_00001813_200206000_00007 crossref_primary_10_1186_1748_717X_5_102 crossref_primary_10_1002__SICI_1097_0347_199908_21_5_402__AID_HED4_3_0_CO_2_Z crossref_primary_10_1002_hed_10034 crossref_primary_10_1016_j_oraloncology_2016_11_016 crossref_primary_10_1007_s40136_014_0040_2 crossref_primary_10_1177_014556130908800610 crossref_primary_10_1007_s10266_019_00451_5 crossref_primary_10_1016_j_oraloncology_2006_01_001 crossref_primary_10_1016_S1470_2045_10_70245_X crossref_primary_10_1136_bcr_2018_227128 crossref_primary_10_1158_1535_7163_MCT_05_0228 crossref_primary_10_1007_s12156_008_0062_4 crossref_primary_10_5402_2012_872982 crossref_primary_10_1177_0194599812464020 crossref_primary_10_1177_1010428320980568 crossref_primary_10_1017_S0022215100131299 crossref_primary_10_1097_01_coc_0000203756_36866_17 crossref_primary_10_1007_s10637_009_9337_2 crossref_primary_10_1016_j_oraloncology_2022_105945 crossref_primary_10_1093_oxfordjournals_annonc_a010770 crossref_primary_10_1002_hed_21458 crossref_primary_10_1053_j_seminoncol_2008_03_009 crossref_primary_10_1016_j_scr_2017_04_003 crossref_primary_10_1016_j_anorl_2023_11_009 crossref_primary_10_1016_j_ajoms_2013_09_013 crossref_primary_10_5631_jibirin_109_557 crossref_primary_10_1007_s11864_022_01001_y crossref_primary_10_1016_j_path_2020_10_001 crossref_primary_10_1016_j_anorl_2023_11_004 crossref_primary_10_1177_014556131709600608 crossref_primary_10_1002_hed_25020 crossref_primary_10_3892_mco_2022_2568 crossref_primary_10_1016_j_ejca_2023_113353 crossref_primary_10_1007_BF01195348 crossref_primary_10_1093_oxfordjournals_annonc_a058665 crossref_primary_10_1186_1758_3284_4_19 crossref_primary_10_1016_j_oraloncology_2012_05_004 crossref_primary_10_1016_j_oraloncology_2013_05_004 crossref_primary_10_3171_2015_1_JNS142462 crossref_primary_10_3390_ijms232314891 crossref_primary_10_1002_hed_20274 crossref_primary_10_1016_j_suronc_2003_10_002 crossref_primary_10_1016_j_oraloncology_2016_12_016 crossref_primary_10_1002_ijc_21514 crossref_primary_10_1016_j_bbcan_2021_188523 crossref_primary_10_1002_1097_0142_19950215_75_4_908__AID_CNCR2820750403_3_0_CO_2_Z crossref_primary_10_1002_hed_24933 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/hed.2880140403 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
ExternalDocumentID | 1381339 |
Genre | Journal Article |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BROTX BRXPI BY8 C45 CGR CS3 CUY CVF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EBD EBS ECM EIF EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB NPM O66 O9- OIG OVD P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~WT |
ID | FETCH-LOGICAL-c4733-b229beacec18bd0673bb7b0dba3163d1296ad219c03e5d3a81457f4774a4bd9a2 |
ISSN | 1043-3074 |
IngestDate | Sat Sep 28 07:21:37 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4733-b229beacec18bd0673bb7b0dba3163d1296ad219c03e5d3a81457f4774a4bd9a2 |
PMID | 1381339 |
ParticipantIDs | pubmed_primary_1381339 |
PublicationCentury | 1900 |
PublicationDate | July/August 1992 |
PublicationDateYYYYMMDD | 1992-07-01 |
PublicationDate_xml | – month: 07 year: 1992 text: July/August 1992 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Head & neck |
PublicationTitleAlternate | Head Neck |
PublicationYear | 1992 |
SSID | ssj0003642 |
Score | 1.6369015 |
Snippet | Nineteen patients, nine men and 10 women, with advanced adenoid cystic carcinoma (ACC), were treated with cisplatin either alone or in combination with... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 273 |
SubjectTerms | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin - administration & dosage Bleomycin - adverse effects Carcinoma, Adenoid Cystic - drug therapy Carcinoma, Adenoid Cystic - mortality Cisplatin - administration & dosage Cisplatin - adverse effects Cisplatin - therapeutic use Doxorubicin - administration & dosage Doxorubicin - adverse effects Female Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - mortality Humans Male Middle Aged Neoplasm Recurrence, Local - epidemiology Remission Induction Retrospective Studies Treatment Outcome |
Title | Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck |
URI | https://www.ncbi.nlm.nih.gov/pubmed/1381339 |
Volume | 14 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LTwIxEG5EY8LFaJT4Tg_eyOLutvs6GtQQE4kHINxIX0Si7BLEg_56pw9YwEfUy4ZsS7N0PqYz2_m-InQRcSriLOJenCWQoATM9xiRwhvGjCvJGMkM6_2-Hbe69K4f9csdXcMumfGGeP-SV_Ifq8I9sKtmyf7BsotB4QZ8BvvCFSwM11_ZuDl6mehattzTi5GsgwHGjlFl6HyLDX4G3qUYQYc3Lcus5ajFKC_GbF4hAB7ZSLbWc-VE8l282tINGh2LBlv02mKOs1BWDF-Dg3h9lhYCDyXpoQe-v5g-ORJIecqz1v-c6tob-xLafUE6Rl5ZrDr3mXoDH1wFXXGqdAk8dNlD2pNLPnluqwT7qGQjTFMj-uOvdISZn4yNHQMIMohVQPqxcU1H27VUUCVJtSts69c6bskmMbXb4u6XzNU9_fBy9YmqaNuNs5aGmHCks4t2XB6Brywo9tCGyvdRbw0QeBkQeJTjOSCwAwS2gMALQOBiiKE_1oDAAAis7X6Aurc3nWbLcwdneIImhHg8DDMOK6oSQcqlPoqI84T7kjMC4beEEC9mEpYq4RMVScLSgEbJkEImwCiXGQtraDMvcnWIMGFEQIaqaUQwdpAwziVRJBS-UbhPj1DNTsNgYtVRBm5-jr9rOEHVEkWnaGsIf0Z1BpHdjJ8bq3wAdnxJ-A |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cisplatin-based+chemotherapy+in+advanced+adenoid+cystic+carcinoma+of+the+head+and+neck&rft.jtitle=Head+%26+neck&rft.au=de+Haan%2C+L+D&rft.au=De+Mulder%2C+P+H&rft.au=Vermorken%2C+J+B&rft.au=Schornagel%2C+J+H&rft.date=1992-07-01&rft.issn=1043-3074&rft.volume=14&rft.issue=4&rft.spage=273&rft_id=info:doi/10.1002%2Fhed.2880140403&rft_id=info%3Apmid%2F1381339&rft_id=info%3Apmid%2F1381339&rft.externalDocID=1381339 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-3074&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-3074&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-3074&client=summon |